ILCA 2024 | Dr. Guohong Han: Exploring Advances and Prospects in Liver Cancer Treatment

ILCA 2024 | Dr. Guohong Han: Exploring Advances and Prospects in Liver Cancer Treatment

Liver cancer is a major global health threat, and ongoing exploration into treatment strategies remains a focal point in medical research. From October 17 to 19, 2024, top experts and scholars in the field of liver cancer gathered in Toronto, Canada, for the 18th International Liver Cancer Association (ILCA) Annual Meeting. This conference brought together leading researchers from around the world to discuss the latest progress and future directions in liver cancer treatment. Oncology Frontier invited Dr. Guohong Han, Executive Dean of the Digestive Hospital at Xi’an International Medical Center Hospital, to provide an insightful interpretation of the conference highlights.
ESMO 2024| Dr. Zhen Cai: Progress in Immunotherapy for Multiple Myeloma and New Perspectives on MRD Detection

ESMO 2024| Dr. Zhen Cai: Progress in Immunotherapy for Multiple Myeloma and New Perspectives on MRD Detection

CAR-T therapy and bispecific antibodies, two innovative immunotherapies, have shown significant efficacy in patients with relapsed/refractory multiple myeloma (RRMM). But how do these two therapies compare in clinical practice? Minimal Residual Disease (MRD) detection is an important tool for evaluating treatment response and prognosis in multiple myeloma (MM), but its application in clinical settings is still limited. How can MRD use be further promoted? At the recent European Society for Medical Oncology (ESMO) Congress 2024, two pivotal studies delved into these questions, sparking widespread attention. This article features insights from Dr. Zhen Cai of The First Affiliated Hospital of Zhejiang University School of Medicine on these studies.
CSCO 2024 | Dr. Lei Tang: Advancements in Modern Imaging Support Immunotherapy Evaluation for Gastric Cancer

CSCO 2024 | Dr. Lei Tang: Advancements in Modern Imaging Support Immunotherapy Evaluation for Gastric Cancer

The 27th Annual Conference of the Chinese Society of Clinical Oncology (CSCO) took place in Xiamen from September 25–29, 2024. This year’s theme, “Patient-Centered, Sharing the Future,” brought together groundbreaking research and developments. Dr. Lei Tang from Peking University Cancer Hospital delivered an insightful presentation on the current state and challenges of imaging in evaluating gastric cancer immunotherapy. In a post-conference interview, he discussed key aspects of imaging evaluation for immunotherapy in gastric cancer.
Dr. Guangyu Liu: Redefining Beauty—Current Status and Future of Breast Reconstruction Techniques |16th Shanghai Breast Reconstruction Conference

Dr. Guangyu Liu: Redefining Beauty—Current Status and Future of Breast Reconstruction Techniques |16th Shanghai Breast Reconstruction Conference

Breast cancer is one of the most common malignancies among women, and while treatment methods continue to improve, maintaining patients' quality of life while extending their survival remains a key focus in the medical community. With the emergence of oncoplastic surgery (OPS) and fat grafting techniques, the post-operative quality of life for breast cancer patients has significantly improved. At the Sixteenth Shanghai Breast Reconstruction Conference, Oncology Frontier invited Dr. Guangyu Liu from Fudan University Shanghai Cancer Center to deeply explore the latest advancements, clinical applications, and future development trends in breast reconstruction techniques. Prof. Liu shared valuable experiences and insights on how OPS helps achieve better breast shape and function, the use of fat grafting in breast reconstruction, the timing and order of reconstruction surgery with adjuvant therapy, and the future trends in breast reconstruction.
Dr. Lanfang Li and Dr. Weiyun Zhuang Discuss Mycosis Fungoides and Sézary Syndrome

Dr. Lanfang Li and Dr. Weiyun Zhuang Discuss Mycosis Fungoides and Sézary Syndrome

The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lanfang Li from the Tianjin Medical University Cancer Institute and Hospital and Dr. Weiyun Zhuang from the University of California, San Francisco (UCSF) School of Medicine, to engage in a China-International dialogue, reviewing the latest treatment strategies for mycosis fungoides (MF) and Sézary syndrome (SS).
IMS 2024丨Dr. Juan Li’s Team: Tandem ASCT as a Potentially Effective Strategy for High-Risk MM Patients with Dual Hits of 1q21 Amplification and t(4;14)

IMS 2024丨Dr. Juan Li’s Team: Tandem ASCT as a Potentially Effective Strategy for High-Risk MM Patients with Dual Hits of 1q21 Amplification and t(4;14)

From September 25 to 28, 2024, the 21st International Myeloma Society (IMS) Annual Meeting was held in Rio de Janeiro, Brazil. At this prestigious conference, the research led by Dr. Juan Li from The First Affiliated Hospital of Sun Yat-sen University in China was selected for poster presentation. The study suggests that for high-risk multiple myeloma (MM) patients with dual hits of 1q21 amplification and t(4;14), tandem autologous stem cell transplantation (Tandem ASCT) might be an effective treatment strategy. Hematology Frontier invited Professor Li to share the findings of this study and its clinical significance.
Dr. Biyun Wang: Early Exploration and Future Prospects of the Novel ADC Drug GQ1005 in HER2-Low Breast Cancer and HER2-Positive Gastric Cancer

Dr. Biyun Wang: Early Exploration and Future Prospects of the Novel ADC Drug GQ1005 in HER2-Low Breast Cancer and HER2-Positive Gastric Cancer

At the 2024 ESMO Conference, the Phase 1a/1b study of the novel drug GQ1005, led by Dr. Biyun Wang from Fudan University Shanghai Cancer Center, was showcased as a poster presentation, garnering significant attention. This study not only confirmed the efficacy and safety of GQ1005 in HER2-low breast cancer and HER2-positive gastric cancer but also laid a solid foundation for its future clinical applications. We invited Dr. Biyun Wang to delve into the background, study design, preliminary efficacy, and safety data of the GQ1005 Phase 1a/1b study, while also discussing its promising future in combination therapies.
China’s Prestigious Oncology Event: 2024 CSCO Annual Meeting Held in Xiamen

China’s Prestigious Oncology Event: 2024 CSCO Annual Meeting Held in Xiamen

Xiamen, China, September 25-29, 2024 — The 27th National Clinical Oncology Conference and the 2024 Academic Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) commenced in Xiamen, embracing the theme "Patient-Centric, Shared Future." Jointly organized by the CSCO and the CSCO Foundation, the conference has brought together top experts and elites in oncology from both domestic and international fields to discuss the latest advancements, cutting-edge technologies, and future trends in cancer prevention and treatment.
Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients

Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients

From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting is being held in Barcelona, Spain. As one of the top international oncology conferences, the event gathers experts and scholars from around the world to share cutting-edge research and discuss future developments. In the Mini Oral Session on Hematologic Malignancies, Dr. Ling Pan from West China Hospital, Sichuan University, presented a pivotal phase II study comparing rovatirelinib with hydroxyurea for the treatment of intermediate and high-risk myelofibrosis (MF). The results demonstrated significant benefits in both efficacy and safety for rovatirelinib, offering a new potential treatment option for MF patients. Hematology Frontier invited Dr. Ling Pan to discuss the current landscape and challenges in the diagnosis and treatment of MF, provide insights into this pivotal study, and share her experiences at the ESMO conference.